002332 仙琚制药
已收盘 08-23 15:00:00
资讯
新帖
简况
仙琚制药:据了解奥美克松钠目前在准备申报阶段
证券之星 · 08-23 16:21
仙琚制药:据了解奥美克松钠目前在准备申报阶段
仙琚制药(002332)8月22日主力资金净卖出27.06万元
证券之星 · 08-23 09:16
仙琚制药(002332)8月22日主力资金净卖出27.06万元
仙琚制药:截止近期,公司股东人数为2万5千余人
证券之星 · 08-22 18:04
仙琚制药:截止近期,公司股东人数为2万5千余人
仙琚制药最新公告:公司甲泼尼龙片4mg被批准注册
证券之星 · 08-21
仙琚制药最新公告:公司甲泼尼龙片4mg被批准注册
仙琚制药(002332.SZ):甲泼尼龙片4mg被批准注册
智通财经 · 08-21
仙琚制药(002332.SZ):甲泼尼龙片4mg被批准注册
仙琚制药:截止近期,公司股东人数为2万5千余人
证券之星 · 08-13
仙琚制药:截止近期,公司股东人数为2万5千余人
德邦证券:给予仙琚制药买入评级
证券之星 · 08-02
德邦证券:给予仙琚制药买入评级
德邦证券给予仙琚制药买入评级,甾体激素龙头全面升级,多重催化打造第二增长曲线
每日经济新闻 · 08-02
德邦证券给予仙琚制药买入评级,甾体激素龙头全面升级,多重催化打造第二增长曲线
德邦证券8月2日发布研报称,给予仙琚制药(002332.SZ)买入评级。评级理由主要包括:1)甾体激素行业龙头,原料药制剂一体化提供增长动能;
智通财经 · 08-02
德邦证券8月2日发布研报称,给予仙琚制药(002332.SZ)买入评级。评级理由主要包括:1)甾体激素行业龙头,原料药制剂一体化提供增长动能;
仙琚制药:截止近期,公司股东人数为2万4千余人
证券之星 · 08-01
仙琚制药:截止近期,公司股东人数为2万4千余人
仙琚制药:截止近期,公司股东人数为2万4千余人
证券之星 · 07-23
仙琚制药:截止近期,公司股东人数为2万4千余人
【机构调研记录】财通基金调研仙琚制药、达梦数据等4只个股(附名单)
证券之星 · 07-22
【机构调研记录】财通基金调研仙琚制药、达梦数据等4只个股(附名单)
【机构调研记录】富国基金刘莉莉调研仙琚制药
证券之星 · 07-22
【机构调研记录】富国基金刘莉莉调研仙琚制药
仙琚制药:7月17日接受机构调研,财通基金、富国基金等多家机构参与
证券之星 · 07-19
仙琚制药:7月17日接受机构调研,财通基金、富国基金等多家机构参与
仙琚制药:截止近期,公司股东人数为2万5千余人
证券之星 · 07-15
仙琚制药:截止近期,公司股东人数为2万5千余人
仙琚制药(002332)7月8日主力资金净买入2255.83万元
证券之星 · 07-09
仙琚制药(002332)7月8日主力资金净买入2255.83万元
仙琚制药(002332)7月5日主力资金净买入825.38万元
证券之星 · 07-08
仙琚制药(002332)7月5日主力资金净买入825.38万元
仙琚制药公告,于近日收到国家药品监督管理局下发的醋酸地塞米松片一致性评价受理通知书,醋酸地塞米松片为肾上腺皮质激素类药,主要用于过敏性与自身免疫性炎症性疾病。
华尔街见闻 · 07-05
仙琚制药公告,于近日收到国家药品监督管理局下发的醋酸地塞米松片一致性评价受理通知书,醋酸地塞米松片为肾上腺皮质激素类药,主要用于过敏性与自身免疫性炎症性疾病。
7月5日仙琚制药(002332)龙虎榜数据:机构净买入915.63万元,北向资金净卖出536.35万元
证券之星 · 07-05
7月5日仙琚制药(002332)龙虎榜数据:机构净买入915.63万元,北向资金净卖出536.35万元
仙琚制药最新公告:公司戊酸雌二醇片被批准注册
证券之星 · 07-05
仙琚制药最新公告:公司戊酸雌二醇片被批准注册
暂无数据
公司概况
公司名称:
浙江仙琚制药股份有限公司
所属行业:
医药制造业
上市日期:
2010-01-12
主营业务:
浙江仙琚制药股份有限公司主营业务为甾体原料药和制剂的研制、生产与销售。公司主要产品分为皮质激素类药物、性激素类药物(妇科及计生用药)、麻醉肌松类药物和呼吸科类药物四大类。2023年,在中国医药工业信息中心主办的2023年(第40届)全国医药工业信息年会发布的“2022年度中国医药工业百强榜”中公司位列第70位,同时公司还首次获得“中国医药研发产品线最佳工业企业”“国家企业技术中心”“国家知识产权优势企业”“浙江知识产权示范企业”等诸多荣誉,顺利通过EcoVadis评级荣获银牌勋章。
发行价格:
8.20
{"stockData":{"symbol":"002332","market":"SZ","secType":"STK","nameCN":"仙琚制药","latestPrice":11.85,"timestamp":1724396610000,"preClose":11.89,"halted":0,"volume":6984302,"delay":0,"floatShares":985000000,"shares":989000000,"eps":0.5875,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.04,"latestTime":"08-23 15:00:00","open":11.84,"high":11.93,"low":11.66,"amount":82202500,"amplitude":0.0227,"askPrice":11.85,"askSize":116,"bidPrice":11.83,"bidSize":2,"shortable":0,"etf":0,"ttmEps":0.5875,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1724635800000},"adr":0,"adjPreClose":11.89,"symbolType":"stock","openAndCloseTimeList":[[1724376600000,1724383800000],[1724389200000,1724396400000]],"highLimit":13.08,"lowLimit":10.7,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":989204866,"pbRate":1.99,"roa":"--","roe":"2.58%","epsLYR":0.57,"committee":0.085502,"marketValue":11722000000,"floatMarketCap":11667000000,"peRate":20.170214,"changeRate":-0.0034,"turnoverRate":0.0071,"status":1,"nextConnectDate":"根据港交所公布的数据,今日已停止北向交易,下一个交易日为北京时间 2024-08-26。"},"requestUrl":"/m/hq/s/002332/tweets","defaultTab":"tweets","newsList":[{"id":"2461655946","title":"仙琚制药:据了解奥美克松钠目前在准备申报阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2461655946","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461655946?lang=zh_cn&edition=full","pubTime":"2024-08-23 16:21","pubTimestamp":1724401313,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药(002332)08月23日在投资者关系平台上答复投资者关心的问题。投资者:董秘您好,公司与奥默医药共同研发的新药奥美克松钠目前进度如何,还在进行申报准备吗,按照目前的进度,预计什么时候可以通过审批?仙琚制药董秘:您好!感谢您对公司的关注。据了解奥美克松钠目前在准备申报阶段。以上内容为证券之星据公开信息整理,由智能算法生成,不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082300027816.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999014674.SGD","BK0028","002332","BK0239"],"gpt_icon":0},{"id":"2461233304","title":"仙琚制药(002332)8月22日主力资金净卖出27.06万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2461233304","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461233304?lang=zh_cn&edition=full","pubTime":"2024-08-23 09:16","pubTimestamp":1724375809,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年8月22日收盘,仙琚制药报收于11.89元,上涨0.85%,换手率0.56%,成交量5.48万手,成交额6499.59万元。近5日资金流向一览见下表:仙琚制药融资融券信息显示,融资方面,当日融资买入357.38万元,融资偿还367.48万元,融资净偿还10.1万元。融券方面,融券卖出4100.0股,融券偿还1300.0股,融券余量24.78万股,融券余额294.68万元。仙琚制药主营业务:甾体原料药和制剂的研制、生产与销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082300008855.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","SG9999014674.SGD","BK0239","002332"],"gpt_icon":0},{"id":"2461399789","title":"仙琚制药:截止近期,公司股东人数为2万5千余人","url":"https://stock-news.laohu8.com/highlight/detail?id=2461399789","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461399789?lang=zh_cn&edition=full","pubTime":"2024-08-22 18:04","pubTimestamp":1724321065,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药08月22日在投资者关系平台上答复投资者关心的问题。投资者:请问截止到8月20日收盘公司在册股东人数是多少?截止近期,公司股东人数为2万5千余人。投资者:我司子公司 海盛制药日前将产品维生素D3的价格上调至440元/kg。请问,海盛制药维生素D3年产2000吨的产能是否满产?公司目前主要产品包括皮质激素类药物、性激素类药物、麻醉肌松类药物和呼吸科用药等治疗领域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082200033224.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002332","BK0028","BK0239","SG9999014674.SGD"],"gpt_icon":0},{"id":"2461874814","title":"仙琚制药最新公告:公司甲泼尼龙片4mg被批准注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2461874814","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461874814?lang=zh_cn&edition=full","pubTime":"2024-08-21 16:49","pubTimestamp":1724230184,"startTime":"0","endTime":"0","summary":"仙琚制药公告,公司于近日收到国家药监局核准签发的关于甲泼尼龙片的《药品补充申请批准通知书》,公司甲泼尼龙片4mg被批准注册。甲泼尼龙片临床应用广泛,主要用于治疗风湿性疾病、胶原疾病、皮肤疾病、过敏状态、眼部疾病、呼吸道疾病等。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024082100028692.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","SG9999014674.SGD","002332"],"gpt_icon":0},{"id":"2461811168","title":"仙琚制药(002332.SZ):甲泼尼龙片4mg被批准注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2461811168","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2461811168?lang=zh_cn&edition=full","pubTime":"2024-08-21 16:44","pubTimestamp":1724229873,"startTime":"0","endTime":"0","summary":"智通财经APP讯,仙琚制药(002332.SZ)发布公告,公司于近日收到国家药品监督管理局核准签发的关于甲泼尼龙片的《药品补充申请批准通知书》(证书编号:2024B03743),公司甲泼尼龙片4mg被批准注册。甲泼尼龙是一种人工合成的不含卤素的糖皮质激素药物,具有强大的抗炎、免疫抑制、抗过敏、抗休克等药理作用。甲泼尼龙片临床应用广泛,主要用于治疗风湿性疾病、胶原疾病、皮肤疾病、过敏状态、眼部疾病、呼吸道疾病等。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1167648.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0028","SG9999014674.SGD","002332","BK0239"],"gpt_icon":0},{"id":"2459592199","title":"仙琚制药:截止近期,公司股东人数为2万5千余人","url":"https://stock-news.laohu8.com/highlight/detail?id=2459592199","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2459592199?lang=zh_cn&edition=full","pubTime":"2024-08-13 17:06","pubTimestamp":1723539960,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药(002332)08月13日在投资者关系平台上答复投资者关心的问题。投资者:请问截止8月9日收盘公司在册股东人数多少?谢谢!仙琚制药董秘:您好!截止近期,公司股东人数为2万5千余人。感谢您的关注。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024081300033974.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002332","BK0028","BK0239","SG9999014674.SGD"],"gpt_icon":0},{"id":"2456490223","title":"德邦证券:给予仙琚制药买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2456490223","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456490223?lang=zh_cn&edition=full","pubTime":"2024-08-02 08:30","pubTimestamp":1722558638,"startTime":"0","endTime":"0","summary":"德邦证券股份有限公司周新明,吴明华近期对仙琚制药进行研究并发布了研究报告《甾体激素龙头全面升级,多重催化打造第二增长曲线》,本报告对仙琚制药给出买入评级,当前股价为11.94元。考虑到公司杨府原料药厂区产能有望逐步爬坡,集采影响预计基本出清叠加多款产品获批以及1类新药奥美克松钠的阶段性催化,首次覆盖,给予“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080200012748.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002332","161027"],"gpt_icon":0},{"id":"2456741869","title":"德邦证券给予仙琚制药买入评级,甾体激素龙头全面升级,多重催化打造第二增长曲线","url":"https://stock-news.laohu8.com/highlight/detail?id=2456741869","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456741869?lang=zh_cn&edition=full","pubTime":"2024-08-02 08:28","pubTimestamp":1722558516,"startTime":"0","endTime":"0","summary":"德邦证券08月02日发布研报称,给予仙琚制药(002332.SZ,最新价:11.94元)买入评级。评级理由主要包括:1)甾体激素行业龙头,原料药制剂一体化提供增长动能;2)原料药业务持续铸就高壁垒,前瞻布局高端法规市场;3)制剂集采影响逐步出清,重磅创新药奥美克松钠申报在即。风险提示:产能利用率增长不及预期;医药政策变动或不及预期;产品销售不及预期;研发进度不及预期。文章来源:每日经济新闻原标题:德邦证券给予仙琚制药买入评级,甾体激素龙头全面升级,多重催化打造第二增长曲线","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408020837529f06ded4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202408020837529f06ded4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["603056","161027","002332"],"gpt_icon":0},{"id":"2456490909","title":"德邦证券8月2日发布研报称,给予仙琚制药(002332.SZ)买入评级。评级理由主要包括:1)甾体激素行业龙头,原料药制剂一体化提供增长动能;","url":"https://stock-news.laohu8.com/highlight/detail?id=2456490909","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456490909?lang=zh_cn&edition=full","pubTime":"2024-08-02 08:26","pubTimestamp":1722558407,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=astock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["161027","BK1574","SG9999014674.SGD","BK1161","002332","BK0028","06978","BK0239","159992"],"gpt_icon":0},{"id":"2456106003","title":"仙琚制药:截止近期,公司股东人数为2万4千余人","url":"https://stock-news.laohu8.com/highlight/detail?id=2456106003","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2456106003?lang=zh_cn&edition=full","pubTime":"2024-08-01 18:04","pubTimestamp":1722506658,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药08月01日在投资者关系平台上答复投资者关心的问题。截止近期,公司股东人数为2万4千余人。请问在整个D3市场占比多少?公司目前主要产品包括皮质激素类药物、性激素类药物、麻醉肌松类药物和呼吸科用药等治疗领域。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024080100035960.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002332","BK0239","SG9999014674.SGD"],"gpt_icon":0},{"id":"2453081587","title":"仙琚制药:截止近期,公司股东人数为2万4千余人","url":"https://stock-news.laohu8.com/highlight/detail?id=2453081587","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453081587?lang=zh_cn&edition=full","pubTime":"2024-07-23 18:04","pubTimestamp":1721729066,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药(002332)07月23日在投资者关系平台上答复投资者关心的问题。投资者:请问截止7月19号收盘公司在册股东人数多少?谢谢!仙琚制药董秘:您好!截止近期,公司股东人数为2万4千余人。感谢您的关注。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072300034772.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","SG9999014674.SGD","002332"],"gpt_icon":0},{"id":"2453720173","title":"【机构调研记录】财通基金调研仙琚制药、达梦数据等4只个股(附名单)","url":"https://stock-news.laohu8.com/highlight/detail?id=2453720173","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453720173?lang=zh_cn&edition=full","pubTime":"2024-07-22 08:02","pubTimestamp":1721606562,"startTime":"0","endTime":"0","summary":"财通基金成立于2011年,截至目前,资产管理规模920.23亿元,排名63/204;资产管理规模703.26亿元,排名60/204;管理公募基金数91只,排名70/204;旗下公募基金经理15人,排名87/204。旗下最近一年表现最佳的公募基金产品为财通福佑定开混合发起,最新单位净值为1.55,近一年增长62.35%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072200001645.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002332","BK0028","BK0231","SG9999014674.SGD","BK0239","688692"],"gpt_icon":0},{"id":"2453320120","title":"【机构调研记录】富国基金刘莉莉调研仙琚制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2453320120","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2453320120?lang=zh_cn&edition=full","pubTime":"2024-07-22 08:02","pubTimestamp":1721606529,"startTime":"0","endTime":"0","summary":"5)磁谷科技 磁谷科技2024年一季报显示,公司主营收入4366.51万元,同比上升19.83%;归母净利润71.9万元,同比上升158.79%;扣非净利润-370.17万元,同比下降53.49%;负债率29.57%,投资收益29.9万元,财务费用-102.31万元,毛利率33.42%。10)安利股份 个股亮点:公司作为苹果公司合格供应商,主要为苹果公司有关产品及配件指定的代工厂和相关企业提供生态功能性合成革材料。旗下最近一年表现最佳的公募基金产品为富国上海金ETF,最新单位净值为5.41,近一年增长21.01%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024072200001597.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999014674.SGD","BK0028","002332","BK0239"],"gpt_icon":0},{"id":"2452492010","title":"仙琚制药:7月17日接受机构调研,财通基金、富国基金等多家机构参与","url":"https://stock-news.laohu8.com/highlight/detail?id=2452492010","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2452492010?lang=zh_cn&edition=full","pubTime":"2024-07-19 11:22","pubTimestamp":1721359335,"startTime":"0","endTime":"0","summary":"证券之星消息,2024年7月19日仙琚制药发布公告称公司于2024年7月17日接受机构调研,财通基金张胤 王靖瑄、富国基金李琰 刘莉莉 蒲世林 吕洋楠、广发证券方程嫣、华创证券王宏雨、银华基金薄官辉 吴颖 罗震寰 刘辉 王利刚 陈晓雅 秦锋 岳梅梅 华强强、招商证券许菲菲 侯彪参与。目前该产品销售态势良好。公司正积极开展药品上市相关工作。仙琚制药主营业务:甾体原料药和制剂的研制、","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071900022210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002332","BK0239","SG9999014674.SGD"],"gpt_icon":0},{"id":"2451619877","title":"仙琚制药:截止近期,公司股东人数为2万5千余人","url":"https://stock-news.laohu8.com/highlight/detail?id=2451619877","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2451619877?lang=zh_cn&edition=full","pubTime":"2024-07-15 17:03","pubTimestamp":1721034236,"startTime":"0","endTime":"0","summary":"证券之星消息,仙琚制药(002332)07月15日在投资者关系平台上答复投资者关心的问题。投资者:请问截止7月10号公司股东人数多少?谢谢!仙琚制药董秘:您好!截止近期,公司股东人数为2万5千余人。感谢您的关注。投资者:您好!请问截至7月10号,公司股东人数是多少?谢谢!仙琚制药董秘:您好!截止近期,公司股东人数为2万5千余人。感谢您的关注。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071500022735.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","SG9999014674.SGD","BK0028","002332"],"gpt_icon":0},{"id":"2450584120","title":"仙琚制药(002332)7月8日主力资金净买入2255.83万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450584120","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2450584120?lang=zh_cn&edition=full","pubTime":"2024-07-09 09:21","pubTimestamp":1720488108,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月8日收盘,仙琚制药报收于11.14元,下跌4.95%,换手率2.35%,成交量23.16万手,成交额2.61亿元。近5日资金流向一览见下表:仙琚制药融资融券信息显示,融资方面,当日融资买入1192.61万元,融资偿还484.63万元,融资净买入707.98万元。仙琚制药主营业务:甾体原料药和制剂的研制、生产与销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070900014022.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["SG9999014674.SGD","BK0028","002332","BK0239"],"gpt_icon":0},{"id":"2449279750","title":"仙琚制药(002332)7月5日主力资金净买入825.38万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449279750","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449279750?lang=zh_cn&edition=full","pubTime":"2024-07-08 09:10","pubTimestamp":1720401052,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月5日收盘,仙琚制药报收于11.72元,上涨10.05%,涨停,换手率1.91%,成交量18.8万手,成交额2.13亿元。近5日资金流向一览见下表:仙琚制药融资融券信息显示,融资方面,当日融资买入413.97万元,融资偿还803.81万元,融资净偿还389.84万元。融券方面,融券卖出7.32万股,融券偿还8.79万股,融券余量32.75万股,融券余额383.88万元。仙琚制药主营业务:甾体原料药和制剂的研制、生产与销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070800001814.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","SG9999014674.SGD","002332"],"gpt_icon":0},{"id":"2449068259","title":"仙琚制药公告,于近日收到国家药品监督管理局下发的醋酸地塞米松片一致性评价受理通知书,醋酸地塞米松片为肾上腺皮质激素类药,主要用于过敏性与自身免疫性炎症性疾病。","url":"https://stock-news.laohu8.com/highlight/detail?id=2449068259","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449068259?lang=zh_cn&edition=full","pubTime":"2024-07-05 17:25","pubTimestamp":1720171526,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"live_wallstreetcn","url":"https://wallstreetcn.com/live/a-stock","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://wallstreetcn.com/live/a-stock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_wallstreetcn","symbols":["002332","SG9999014674.SGD","BK0028","BK0239"],"gpt_icon":0},{"id":"2449592522","title":"7月5日仙琚制药(002332)龙虎榜数据:机构净买入915.63万元,北向资金净卖出536.35万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2449592522","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449592522?lang=zh_cn&edition=full","pubTime":"2024-07-05 17:12","pubTimestamp":1720170736,"startTime":"0","endTime":"0","summary":"证券之星消息,沪深交易所2024年7月5日公布的交易公开信息显示,仙琚制药因日涨幅偏离值达到7%的前5只证券登上龙虎榜。此次是近5个交易日内第1次上榜。截至2024年7月5日收盘,仙琚制药报收于11.72元,上涨10.05%,涨停,换手率1.91%,成交量18.8万手,成交额2.13亿元。从龙虎榜公布的当日买卖数据来看,机构合计净买入915.63万元,北向资金合计净卖出536.35万元。从龙虎榜数据可以发现和研究机构、游资和散户的资金动向。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500034283.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","SG9999014674.SGD","BK0239","002332"],"gpt_icon":0},{"id":"2449625926","title":"仙琚制药最新公告:公司戊酸雌二醇片被批准注册","url":"https://stock-news.laohu8.com/highlight/detail?id=2449625926","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2449625926?lang=zh_cn&edition=full","pubTime":"2024-07-05 17:09","pubTimestamp":1720170579,"startTime":"0","endTime":"0","summary":"仙琚制药公告,公司于近日收到国家药品监督管理局核准签发的关于戊酸雌二醇片的《药品注册证书》(证书编号:2024S01558),公司戊酸雌二醇片被批准注册。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500034172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002332","BK0239","SG9999014674.SGD","BK0028"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2010-01-12","address":"浙江省台州市仙居县仙药路1号","stockEarnings":[{"period":"1week","weight":-0.0287},{"period":"1month","weight":0.0753},{"period":"3month","weight":-0.0207},{"period":"6month","weight":0.1403},{"period":"1year","weight":0.0892},{"period":"ytd","weight":-0.049}],"companyName":"浙江仙琚制药股份有限公司","boardCode":"AI0027","perCapita":"39382股","boardName":"医药制造业","registeredCapital":"98920万元","compareEarnings":[{"period":"1week","weight":-0.0087},{"period":"1month","weight":-0.0164},{"period":"3month","weight":-0.0759},{"period":"6month","weight":-0.0501},{"period":"1year","weight":-0.0739},{"period":"ytd","weight":-0.0405}],"survey":" 浙江仙琚制药股份有限公司主营业务为甾体原料药和制剂的研制、生产与销售。公司主要产品分为皮质激素类药物、性激素类药物(妇科及计生用药)、麻醉肌松类药物和呼吸科类药物四大类。2023年,在中国医药工业信息中心主办的2023年(第40届)全国医药工业信息年会发布的“2022年度中国医药工业百强榜”中公司位列第70位,同时公司还首次获得“中国医药研发产品线最佳工业企业”“国家企业技术中心”“国家知识产权优势企业”“浙江知识产权示范企业”等诸多荣誉,顺利通过EcoVadis评级荣获银牌勋章。","serverTime":1724566365702,"listedPrice":8.2,"stockholders":"25000人(较上一季度增加4.17%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.26.2","shortVersion":"4.26.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"仙琚制药(002332)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供仙琚制药(002332)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"仙琚制药,002332,仙琚制药股票,仙琚制药股票老虎,仙琚制药股票老虎国际,仙琚制药行情,仙琚制药股票行情,仙琚制药股价,仙琚制药股市,仙琚制药股票价格,仙琚制药股票交易,仙琚制药股票购买,仙琚制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"仙琚制药(002332)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供仙琚制药(002332)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}